Alec Stranahan
Stock Analyst at B of A Securities
(0.66)
# 4,065
Out of 5,182 analysts
29
Total ratings
39.29%
Success rate
-67.31%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Alec Stranahan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| WVE Wave Life Sciences | Maintains: Buy | $38 → $21 | $6.94 | +202.59% | 1 | Mar 27, 2026 | |
| KRYS Krystal Biotech | Maintains: Buy | $288 → $318 | $272.75 | +16.59% | 6 | Jan 22, 2026 | |
| CADL Candel Therapeutics | Downgrades: Neutral | $13 → $7 | $6.29 | +11.29% | 2 | Sep 3, 2025 | |
| XNCR Xencor | Downgrades: Neutral | $23 → $12 | $13.10 | -8.40% | 2 | Sep 3, 2025 | |
| ERAS Erasca | Downgrades: Underperform | $4 → $1 | $19.15 | -94.78% | 3 | Sep 3, 2025 | |
| NVAX Novavax | Downgrades: Underperform | $9 → $7 | $8.07 | -13.26% | 5 | Aug 20, 2025 | |
| BEAM Beam Therapeutics | Upgrades: Buy | $42 | $29.17 | +44.01% | 1 | Mar 28, 2025 | |
| CRBU Caribou Biosciences | Maintains: Buy | $13 → $11 | $2.13 | +416.43% | 1 | Jan 7, 2025 | |
| CATX Perspective Therapeutics | Downgrades: Neutral | $24 → $6 | $4.27 | +40.52% | 2 | Nov 25, 2024 | |
| EDIT Editas Medicine | Upgrades: Buy | $13 → $15 | $2.89 | +419.03% | 1 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $48 → $55 | $131.67 | -58.23% | 3 | Jul 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $5 → $6 | $35.38 | -83.04% | 2 | Dec 29, 2022 |
Wave Life Sciences
Mar 27, 2026
Maintains: Buy
Price Target: $38 → $21
Current: $6.94
Upside: +202.59%
Krystal Biotech
Jan 22, 2026
Maintains: Buy
Price Target: $288 → $318
Current: $272.75
Upside: +16.59%
Candel Therapeutics
Sep 3, 2025
Downgrades: Neutral
Price Target: $13 → $7
Current: $6.29
Upside: +11.29%
Xencor
Sep 3, 2025
Downgrades: Neutral
Price Target: $23 → $12
Current: $13.10
Upside: -8.40%
Erasca
Sep 3, 2025
Downgrades: Underperform
Price Target: $4 → $1
Current: $19.15
Upside: -94.78%
Novavax
Aug 20, 2025
Downgrades: Underperform
Price Target: $9 → $7
Current: $8.07
Upside: -13.26%
Beam Therapeutics
Mar 28, 2025
Upgrades: Buy
Price Target: $42
Current: $29.17
Upside: +44.01%
Caribou Biosciences
Jan 7, 2025
Maintains: Buy
Price Target: $13 → $11
Current: $2.13
Upside: +416.43%
Perspective Therapeutics
Nov 25, 2024
Downgrades: Neutral
Price Target: $24 → $6
Current: $4.27
Upside: +40.52%
Editas Medicine
Aug 8, 2024
Upgrades: Buy
Price Target: $13 → $15
Current: $2.89
Upside: +419.03%
Jul 16, 2024
Maintains: Buy
Price Target: $48 → $55
Current: $131.67
Upside: -58.23%
Dec 29, 2022
Maintains: Underperform
Price Target: $5 → $6
Current: $35.38
Upside: -83.04%